ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
The recent regulatory approval for ProQR’s investigational therapy enables progression to clinical trials, potentially impacting the company’s valuati...
Read Full Article →